Tocris History
Working with Scientists for More Than 35 Years
Tocris Bioscience is the trading name of Tocris Cookson Ltd., which is headquartered in Bristol, UK. The company was founded in 1982 by Professor Jeff Watkins from the University of Bristol's pharmacology department. It began as a specialized provider of neuroscience reagents (specifically glutamate compounds) to make novel research tools easily accessible to the global scientific community.
Key Milestones in Tocris' history
| 1982 | Tocris Neuramin founded by Professor Jeff Watkins in Bristol, UK. |
| 1985 | Cookson Chemicals founded by Professor Richard Cookson in Southampton, UK. |
| 1994 | Tocris Neuramin and Cookson Chemicals merge to form Tocris Cookson Ltd. |
| 1995 | US subsidiary Tocris Cookson Inc., opens in St Louis, MO. |
| 2002 | Tocris receives Queen's Award for Enterprise in the international trade category |
| 2005 | Tocris Bioscience brand launched to reflect its expanding catalog of bioactive Small Molecules |
| 2006 | Founders retire – MBO |
| 2011 | Tocris Bioscience joins R&D Systems to broaden their life science reagents offering. |
| 2014 | Techne Corporation operates under new name, Bio-Techne |
| 2016 | Tocris Bioscience move into state-of-the-art facilities in Bristol, UK. |
| 2021 | Bristol manufacturing facility achieve ISO 9001:2015 Quality Management Systems certification. |
Tocris Neuramin was founded in 1982 by Professor Jeff Watkins of the Pharmacology Department at the University of Bristol, UK. Watkins' research interests focused on glutamate receptors and their involvement in the synaptic transmission processes of the mammalian central nervous system. Tocris Neuramin was founded to make standard research tools and novel probes in this field easily available to researchers, at least partly in response to the number of requests for samples Watkins was receiving at the time.[1]
Cookson Chemicals was formed in 1985 by Richard Cookson, Professor of Organic Chemistry at the University of Southampton, UK. Cookson Chemicals provided custom synthesis services as well as a range of neurochemicals to the pharmaceutical and allied industries.
Tocris Cookson Ltd was incorporated in the UK in July 1994 as the result of a merger between Tocris Neuramin Ltd of Bristol, UK and Cookson Chemicals Ltd of Southampton, UK.
In 2002 Tocris Cookson was awarded The Queen's Awards for Enterprise in the International Trade category and later in 2006 received nominations in five categories of the prestigious Life Science Industry Awards.
In October 2005 Tocris announced the opening of new laboratories at the IO Centre, Bristol, UK. At this time, to reflect the increasingly biological nature of the products and customer base the trading name was changed to Tocris Bioscience.
In January 2007 Tocris Bioscience announced the successful completion of a $40 million management buy-out (MBO) deal, providing Tocris with the ability and freedom to further develop its existing business areas and to offer additional products and services to its international client base.
In May 2011 Tocris Bioscience announced that it was combining with R&D Systems. R&D Systems' products include a wide selection of biotechnology-based tools for cell biology research including proteins, antibodies, assays and kits. To learn more about the company and their products visit the R&D Systems website.
In January 2014 Techne Corporation (NASDAQ: TECH) announced that it will operate under a new trade name, Bio-Techne. Over time the new name will be used to unite the company's resources and portfolio to deliver its best-in-class brands and service solutions under a new unified website. The company's major brand names, including Tocris Bioscience, will be maintained.
In January 2016 Tocris Bioscience relocated to a brand new facility at the Avonbridge Trading Estate, Bristol, UK. The facility was named the Watkins Building, after Jeff Watkins, who founded Tocris Neuramin in 1982. The state-of-the-art facility achieve ISO 9011:2015 certification in 2021.
[1] Watkins JC, Jane DE (2006). "The Glutamate Story". British Journal of Pharmacology 147: S100-S108. PMID 16402093.